Targeting the Upstream Pro-Fibrotic Amplifier S100A4: A Differentiated Approach to Treating IPF
- Addressing the complexity of IPF pathogenesis: Mechanistic rationale for targeting S100A4 in fibrosis – an evolutionary conserved amplifier of inflammation and persistent fibrogenesisÂ
- Impact of S100A4 suppression across preclinical and translational assays of fibrosis and inflammation
- Introducing CAL101: A first-in-class anti-S100A4 mAb being evaluated in IPF patients in the phase 2 AURORA study